Content about Pharmaceutical sciences

January 15, 2013

A drug-security product has won a drug-abuse prevention award.

LINCOLN, Calif. — A drug-security product has won a drug-abuse prevention award.

The Locking Cap was named as one of the "Top 5 Technologies to Reduce Prescription Drug Abuse" by the Center for Lawful Access and Abuse Deterrence.

The cap is a four-digit combination-locking lid for prescription medication bottles. The maker of the cap, Cap-n-Lock, launched an updated version of the cap at the beginning of the year to attract the attention of shoppers.

January 11, 2013

A panel of Food and Drug Administration experts has recommended approval for an experimental Type 2 diabetes drug made by Johnson & Johnson, the drug maker said.

RARITAN, N.J. -- A panel of Food and Drug Administration experts has recommended approval for an experimental Type 2 diabetes drug made by Johnson & Johnson, the drug maker said.

J&J said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had recommended approval for canagliflozin, which the company plans to market under the name brand Invokana. The FDA is not required to follow the votes of advisory committees when deciding whether or not to approve a drug, but usually does.

January 11, 2013

Walgreens chief Greg Wasson had a new vision to share with the pharmacy operator's faithful shareholders for 2013. It was a vision that firmly placed the Express Scripts dispute in the rear-view mirror and refocused on the road ahead that includes expanding the role of pharmacy and even what it means to be a U.S. pharmacy operator with its acquisition of Alliance Boots.

Two major announcements were made in the wake of the shareholders meeting, both of which were identified by DSN as two of the top six big trends to watch through 2013. Walgreens reiterated its commitment to fostering an omnichannel experience for its shoppers and, a day after the shareholders meeting, Walgreens became the only retail pharmacy operator to partner on three Accountable Care Organizations.

Walgreens chief Greg Wasson had a new vision to share with the pharmacy operator's faithful shareholders for 2013. It was a vision that firmly placed the Express Scripts dispute in the rear-view mirror and refocused on the road ahead, that includes expanding the role of pharmacy and even what it means to be a U.S. pharmacy operator with its acquisition of Alliance Boots. 

January 10, 2013

The Food and Drug Administration has approved a new intrauterine device for preventing pregnancy made by Bayer HealthCare Pharmaceuticals, the drug maker said.

WAYNE, N.J. — The Food and Drug Administration has approved a new intrauterine device for preventing pregnancy made by Bayer HealthCare Pharmaceuticals, the drug maker said.

Bayer announced the approval of Skyla (levonorgestrel-releasing uterine system), which can prevent pregnancy for up to three years. The IUD contains 13.5 mg of levonorgestrel.

Nearly 50% of pregnancies in the United States are unintended, according to the National Center for Health Statistics.

January 10, 2013

The Food and Drug Administration has approved a generic epilepsy drug made by Wockhardt, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic epilepsy drug made by Wockhardt, the company said.

Wockhardt, based in India, announced the approval of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths.

The drug is a generic version of GlaxoSmithKline's Lamictal XR. The U.S. market for the drug is about $250 million, according to IMS Health.

January 10, 2013

The Food and Drug Administration is ordering the makers of several sleep drugs to lower the dosage due to the risk that they can impair patients the morning after, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration is ordering the makers of several sleep drugs to lower the recommended dosage due to the risk that they can impair patients the morning after, the agency said Thursday.

The FDA announced that it was requiring the manufacturers of drugs containing the active ingredient zolpidem to lower the current recommended dosage in light of new data showing that the morning after use, the drug can remain in the blood in sufficient quantities to impair activities that require alertness, such as driving.

January 9, 2013

"2012 was definitely an important year for Walgreens," Greg Wasson, Walgreens president and CEO, told shareholders here Wednesday afternoon at the chain's annual shareholder meeting. "We did make some tough choices to protect and solidify … our position for the long term," he said. "[But] our vision is crystal clear to become the first choice for health and daily living in America."

 CHICAGO — "[The year] 2012 was definitely an important year for Walgreens," Greg Wasson, Walgreens president and CEO, told shareholders here, at the Navy Pier, Wednesday afternoon, at the chain's annual shareholder meeting. "We did make some tough choices to protect and solidify … our position for the long term," he said. "[But] our vision is crystal clear to become the first choice for health and daily living in America."

January 9, 2013

Generic drug maker Watson Pharmaceuticals has hired a former executive from the Generic Pharmaceutical Association to head lobbying at the federal and state level, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has hired a former executive from the Generic Pharmaceutical Association to head lobbying at the federal and state level, the company said Wednesday.

Watson announced the appointment of James Fenton as VP U.S. government affairs. In the new position, Fenton will work out of Watson's Washington offices and will be responsible for leading the company's expanded federal and state government affairs activities.

January 8, 2013

Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

SAN FRANCISCO — Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

The 2013 California Biomedical Industry Report — by PwC, the California Healthcare Institute and BayBio — looked at California's biotech industry and how it faired in 2012.

January 8, 2013

The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

January 8, 2013

Home care provider ResCare HomeCare announced it has signed a national affiliation agreement with Walgreens as the national drug store chain rolls out its DailyMed by Walgreens prescription service.

LOUISVILLE, Ky. — Home care provider ResCare HomeCare on Tuesday announced that it has signed a national affiliation agreement with Walgreens as the national drug store chain rolls out its DailyMed by Walgreens prescription service.

January 7, 2013

While pressure to grow will drive more large drug makers to pursue mergers and acquisitions, diminished resources and competition from biotech and specialty pharmaceutical companies will challenge their ability to do so, according to a new report.

SAN FRANCISCO — While pressure to grow will drive more large drug makers to pursue mergers and acquisitions, diminished resources and competition from biotech and specialty pharmaceutical companies will challenge their ability to do so, according to a new report.

January 7, 2013

Massachusetts Gov. Deval Patrick has introduced legislation that would give the state government broader power over compounding pharmacies, the governor's office announced.

BOSTON — Massachusetts Gov. Deval Patrick has introduced legislation that would give the state government broader power over compounding pharmacies, the governor's office announced.

January 4, 2013

The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

January 4, 2013

Both the strong incidence of influenza and the rise in the number of flu shots administered in December positively impacted comparable prescriptions filled at Walgreens on a day-fall adjusted basis, the company reported.

DEERFIELD, Ill. — Both the strong incidence of influenza and the rise in the number of flu shots administered in December positively impacted comparable prescriptions filled at Walgreens on a day-fall adjusted basis, the company reported Friday. Flu shots administered at pharmacies and clinics season-to-date were nearly 5.5 million versus approximately 5.3 million last year, the retailer noted. 

January 3, 2013

A patient’s social support network has been associated with improved outcomes and healthier behaviors and now new research sponsored by CVS Caremark has found that practical social support is associated with improved medication adherence.

WOONSOCKET, R.I. — A patient’s social support network has been associated with improved outcomes and healthier behaviors and now new research sponsored by CVS Caremark has found that practical social support is associated with improved medication adherence.

January 3, 2013

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

January 3, 2013

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

January 3, 2013

The Food and Drug Administration has approved a generic drug for heavy menstrual bleeding made by Watson Pharmaceuticals, the drug maker said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for heavy menstrual bleeding made by Watson Pharmaceuticals, the drug maker said Thursday.

Watson announced the approval of tranexamic acid tablets through a subsidiary and plans to ship it immediately. The drug is a generic version of Ferring Pharmaceuticals' Lysteda.

Ferring has filed suit against Watson, alleging that the generic drug infringes two of its patents. Lysteda had sales of about $25 million during the 12-month period that ended in November, according to IMS Health.

January 3, 2013

Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

PEAPACK, N.J. — Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

Greenstone announced the introduction of phenytoin tablets in the 50-mg strength, an authorized generic version of Pfizer's Dilantin Infatabs.

Authorized generics are generic drugs marketed under their generic names at a reduced price, often through third-party companies under contract with the original drug's manufacturer.

January 3, 2013

A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

WASHINGTON — A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

Zuckerman Spaeder LLP said the U.S. District Court for the District of Columbia upheld a Food and Drug Administration decision protecting Ranbaxy's market exclusivity for a generic version of Novartis' drug Diovan (valsartan).

January 3, 2013

A shift in the New Year's holiday calendar and the introduction of new generic drugs contributed to a decrease in same-store sales for the month of December at Rite Aid, the retail pharmacy chain said.

CAMP HILL, Pa. — A shift in the New Year's holiday calendar and the introduction of new generic drugs contributed to a decrease in same-store sales for the month of December at Rite Aid, the retail pharmacy chain said Thursday.

January 2, 2013

In 2012, the Food and Drug Administration approved 39 new drugs, 8 alone in December, marking the largest increase in 16 years.

NEW YORK — In 2012, the Food and Drug Administration approved 39 new drugs, 8 alone in December, marking the largest increase in 16 years. The wave of approvals poises pharmaceutical makers to see big gains after billions in losses in recent years to generic drug makers because of patent expirations.

January 2, 2013

The U.S. Food and Drug Administration has approved a new drug from Johnson & Johnson for patients with tuberculosis who do not respond to other treatments, the company announced.

WASHINGTON — The U.S. Food and Drug Administration has approved a new drug from Johnson & Johnson for patients with tuberculosis who do not respond to other treatments, the company announced.

Tuberculosis is an air-spread infection that usually attacks the lungs, but also affect the brain, the spine and the kidneys. The drug blocks an energy-producing enzyme the tuberculosis bacteria needs to survive and is the first drug in 40 years to attempt to cure the disease using this type of treatment.

January 2, 2013

Mylan announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for rizatriptan benzoate orally disintegrating tablets and rizatriptan benzoate tablets, generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets.

PITTSBURGH — Mylan announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for rizatriptan benzoate orally disintegrating tablets, 5 mg and 10 mg, and rizatriptan benzoate tablets, 5 mg and 10 mg. These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt® Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.